Moors & Cabot, Inc. Immuneering Corp Transaction History
Moors & Cabot, Inc.
- $2.17 Billion
- Q3 2025
A detailed history of Moors & Cabot, Inc. transactions in Immuneering Corp stock. As of the latest transaction made, Moors & Cabot, Inc. holds 11,000 shares of IMRX stock, worth $70,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000Holding current value
$70,400% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IMRX
# of Institutions
69Shares Held
14.5MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA2.42MShares$15.5 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$11.5 Million0.0% of portfolio
-
Exodus Point Capital Management, LP New York, NY1.52MShares$9.71 Million0.11% of portfolio
-
Logos Global Management LP San Francisco, CA950KShares$6.08 Million0.72% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il943KShares$6.04 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $169M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...